The Union of AI and Biotech

The union of Artificial Intelligence (AI) and biotechnology is an area of innovation ripe for explosive growth.

PricewaterhouseCooper estimates AI will contribute $15.7 trillion to global output by 2030. Biotech is improving at an extraordinary pace as well. Specifically, in the field of synthetic biology, where the global market is expected to reach $12.5 billion in 2024.

The cost of deciphering the human genome has gone from $3 billion in 2001, to about a thousand dollars now. The process, which took months, can now be done in less than an hour.

The problem is developments within Biotech often take years from research to pre-clinical trials, to FDA approval, to finally reaching the consumer market. Financial engineering has done little to speed this up. With AI applied to biotech, we’ll have the ability to transform the process.

The potential for AI within Biotech is vast; data solutions for drug discovery, diagnostics, medical imaging, and other treatments. AI will innovate the diagnosis and treatment of disease in ways we can only imagine right now.

The coming revolution of AI-enabled Biotechnology will require highly skilled specialists in both fields. Dustin Hoffman had one word in The Graduate; “Plastics!”, but I propose the pioneers of today would have two: “AI-enabled Biotech.”



This is the place for accelerating your career insights on trends in AI and its influence on our work world. Develop a road map that gives your career a strategic advantage. Be ready for the jobs that don’t even exist yet. Sign up now. It's free.


Comments